Pharmaceuticals
Ionis Pharmaceuticals cuts Tryngolza's price by 93%, from $595,000 to $40,000 annually, signaling a strategic shift in rare disease drug pricing ahead of a broader indication approval.
Biotechnology
The FDA's approval of nivolumab plus chemotherapy for previously untreated Stage III and IV classical Hodgkin lymphoma on March 20, 2026 marks the formal arrival of immunotherapy at the front line of one of oncology's most treatable cancers.
Pharmaceuticals
Eli Lilly's Phase 3 retatrutide data reveals a triple-acting metabolic drug that may push weight loss efficacy beyond tirzepatide, with patients losing up to 15% of body weight over 40 weeks—and the trajectory still heading downward.
Pharmaceuticals
The FDA approved IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity on March 19, 2026. Here is what the TRANSCEND trial data mean for patients, the MC4R pathway platform, and the rare disease market.
Pharmaceuticals
For the roughly 125 million people worldwide living with psoriasis, the treatment conversation has long followed a familiar and frustrating arc. Start with topical creams. Cycle through them. Graduate, eventually, to an injectable biologic that requires a needle, a refrigerator, and a willingness to self-administer a shot every few
Pharmaceuticals
Pfizer's Phase 2 FOURLIGHT-1 data on atirmociclib show a 40% reduction in disease progression risk in CDK4/6 inhibitor-resistant breast cancer, positioning the selective CDK4 inhibitor as a potential successor to Ibrance ahead of its 2027 patent expiry.
Biotechnology
Structure Therapeutics' aleniglipron showed 15% weight loss in Phase 2 trials, delivering injectable-like efficacy in pill form and reshaping the competitive landscape for oral GLP-1 obesity drugs.
Pharmaceuticals
Evaluate's 2026 Orphan Drug Report projects rare disease drug sales will exceed $400 billion by 2032. Behind the headline number lies a more complicated story about FDA volatility, IRA policy shifts, and the structural forces reshaping who wins in rare disease medicine.
Pharmaceuticals
On March 9, 2026, Ipsen announced the immediate voluntary withdrawal of Tazverik (tazemetostat) from all markets worldwide. The decision, triggered by safety signals from the ongoing SYMPHONY-1 confirmatory trial, marks one of the more consequential drug withdrawals in recent oncology history. Not because of the commercial stakes, which were
Markets
Eli Lilly's new Employer Connect platform lets workers buy Zepbound at $449/month, bypassing insurers entirely. It is a bold bet that pharma companies can rewrite the rules of drug distribution before compounders and insurers do it for them.
Biotechnology
Zorevunersen becomes the first therapy to show disease modification in Dravet syndrome, offering hope for families through improved seizure control and developmental outcomes.
Pharmaceuticals
In a significant regulatory achievement that could transform treatment options for millions of patients worldwide, Johnson & Johnson announced on March 3, 2026, that the U.S. Food and Drug Administration has granted Fast Track designation to nipocalimab for the treatment of adults with systemic lupus erythematosus (SLE). This milestone